Copyright © 1996 by the European Society of Cardiology.
© 1996 The European Society of Cardiology
Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment
,
*The Clinic of Internal Medicine, Tampere University Hospital Tampere, Finland
The Department of Clinical Sciences, Tampere University Tampere, Finland
Department of Clinical Chemistry, Tampere University Hospital Tampere, Finland
revised 7 February 1996; accepted 7 February 1996.
Correspondence: Kari Pietilä, MD, Clinic of Internal Medicine, Tampere University Hospital, P.O. Box 2000, FIN-3352l0 Tampere, Finland
Abstract
Objectives We studied the relationship between serum C-reactive protein and mortality in acute myocardial infarction.
Background Early recanalization of an infarct-related coronary artery is considered to be an essential prerequisite for reducing mortality by thrombolytic treatment in acute myocardial infarction. It also reduces the inflammatory reaction caused by acute myocardial infarction and is measurable by determination of serum C-reactive protein concentrations. We therefore studied the prognostic value of determining serum C-reactive protein in acute myocardial infarction.
Methods We measured serum C-reactive protein concentrations daily for 6 days and creatine kinase, as well as its MB isoenzyme concentrations twice a day, for 3 days after a myocardial infarct, in 188 consecutive patients selected for thrombolytic therapy and treated in the same University Hospital Coronary Care Unit. The highest serum concentrations were related to total mortality as well as to the causes of death 3, 3–6, 6–12 and 12–24 months after the onset of the myocardial infarction.
Results The highest serum concentrations of serum C-reactive protein were observed 2 to 4 days after the onset of myocardial infarction. The mean value of the highest serum concentration of C-reactive protein in patients who survived the whole 24-month study period was 65 mg. l–1 with the 95% confidence intervals for the mean ranging from 58 to 71. The corresponding values in those who died within 3, 3–6, 6–12 and 12–24 months were 166 (139–194), 136 (88–184), 85 (52–119) and 74 (38–111) mg.l–1 respectively. The values in those who died within 3 and 3–6 months of the infarction differed statistically significantly from the values in those who survived the whole period (P<0.001 and P<0.05, respectively). In patients who died due to congestive heart failure the mean highest serum C-reactive protein concentration was 226 (189–265) mg . l–1 In those who suffered sudden cardiac death and those who died from a new myocardial infarction or non-cardiac causes, the respective values were 167 (138–196), 64 (38–89) and 48 (10–86) mg. l–1. The values in those who died due to congestive heart failure and those suffering sudden cardiac death differed statistically significantly (P<0.001) from the values of those who survived or died due to other causes. The highest serum concentrations of creatine kinase or its MB isoenzyme were not associated with mortality in this study.
Conclusions High serum C-reactive protein concentrations in acute myocardial infarction patients treated with thrombolytic drugs predict increased mortality up to 6 months following the infarction. Accordingly, reduction of inflammatory reaction by successful thrombolytic treat ment may make an important contribution to the survival benefit of thrombolytic treatment of acute myocardial infarction.
Key Words: Myocardial infarction • C-reactive protein • survival • congestive heart failure • sudden cardiac death
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Singh, S. Devaraj, and I. Jialal C-Reactive Protein Stimulates Myeloperoxidase Release from Polymorphonuclear Cells and Monocytes: Implications for Acute Coronary Syndromes Clin. Chem., February 1, 2009; 55(2): 361 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bogaty, L. Boyer, S. Simard, F. Dauwe, R. Dupuis, B. Verret, T. Huynh, F. Bertrand, G. R. Dagenais, and J. M. Brophy Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2339 - 2346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Singh, M. R. Dasu, P. G. Yancey, A. Afify, S. Devaraj, and I. Jialal Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats J. Lipid Res., May 1, 2008; 49(5): 1015 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care Clin. Chem., February 1, 2008; 54(2): 234 - 237. [Full Text] [PDF]
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, C. P. Cannon, J. A. de Lemos, S. Murphy, M. S. Sabatine, S. D. Wiviott, N. Rifai, C. H. McCabe, E. Braunwald, et al. Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes Clin. Chem., October 1, 2007; 53(10): 1800 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]
|
|
|
|
|
|
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziakas, S. Gavrilidis, G. Giannoglou, E. Souliou, K. Gemitzis, D. Kalampalika, M. A. Vayona, I. Pidonia, G. Parharidis, and G. Louridas In-Hospital and Long-Term Prognostic Value of Fibrinogen, CRP, and IL-6 Levels in Patients with Acute Myocardial Infarction Treated with Thrombolysis Angiology, May 1, 2006; 57(3): 283 - 293. [Abstract] [PDF]
|
|
|
|
 |
|
 R. F. Bonvini, T. Hendiri, and E. Camenzind Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I27 - I36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Singh, S. Devaraj, and I. Jialal C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2216 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Biasucci CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper Circulation, December 21, 2004; 110(25): e560 - e567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W. Wong, M. McLean, S. C. Boyages, and N. W. Cheung C-Reactive Protein Levels Following Acute Myocardial Infarction: Effect of insulin infusion and tight glycemic control Diabetes Care, December 1, 2004; 27(12): 2971 - 2973. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Yip, C.-J. Wu, H.-W. Chang, C.-H. Yang, K.-H. Yeh, S. Chua, and M. Fu Levels and Values of Serum High-Sensitivity C-Reactive Protein Within 6 Hours After the Onset of Acute Myocardial Infarction Chest, November 1, 2004; 126(5): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z.H. Rittersma, R. J. de Winter, K. T. Koch, C. E. Schotborgh, M. Bax, G. S. Heyde, J. P. van Straalen, K. J. Mulder, J. G.P. Tijssen, G. T. Sanders, et al. Preprocedural C-Reactive Protein Is Not Associated with Angiographic Restenosis or Target Lesion Revascularization after Coronary Artery Stent Placement Clin. Chem., September 1, 2004; 50(9): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Daneshtalab, R. Z. Lewanczuk, A. Russell, and F. Jamali Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan J. Clin. Pharmacol., March 1, 2004; 44(3): 245 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chaudhuri, D. Janicke, M. F. Wilson, D. Tripathy, R. Garg, A. Bandyopadhyay, J. Calieri, D. Hoffmeyer, T. Syed, H. Ghanim, et al. Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segment-Elevation Myocardial Infarction Circulation, February 24, 2004; 109(7): 849 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Hirschfield and M.B. Pepys C-reactive protein and cardiovascular disease: new insights from an old molecule QJM, November 1, 2003; 96(11): 793 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nijmeijer, W. K. Lagrand, Y. T. P. Lubbers, C. A. Visser, C. J. L. M. Meijer, H. W. M. Niessen, and C. E. Hack C-Reactive Protein Activates Complement in Infarcted Human Myocardium Am. J. Pathol., July 1, 2003; 163(1): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Barrett, J. K. Hennan, R. M. Marks, and B. R. Lucchesi C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1007 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ikeda, Y. Maeda, K. Yamamoto, and K. Shimada C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes Cardiovasc Res, October 1, 2002; 56(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. McGeer and E. G. McGeer Innate Immunity, Local Inflammation, and Degenerative Disease Sci. Aging Knowl. Environ., July 24, 2002; 2002(29): re3 - 3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Berton, R Cordiano, R Palmieri, F Cucchini, R de Toni, and P Palatini Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality Eur. Heart J., August 2, 2001; 22(16): 1466 - 1475. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Di Napoli C reactive protein and acute phase of ischaemic stroke BMJ, June 30, 2001; 322(7302): 1605 - 1605. [Full Text]
|
|
|
|
 |
|
 M. Di Napoli, F. Papa, and V. Bocola C-Reactive Protein in Ischemic Stroke : An Independent Prognostic Factor Stroke, April 1, 2001; 32(4): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Chehata, A. B. Hassell, S. A. Clarke, D. L. Mattey, M. A. Jones, P. W. Jones, and P. T. Dawes Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity Rheumatology, April 1, 2001; 40(4): 447 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques Am. J. Pathol., March 1, 2001; 158(3): 1039 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Zhu, Y Hojo, U Ikeda, K Shimada;, and G F BAXTER Production of hepatocyte growth factor during acute myocardial infarction Heart, April 1, 2000; 83(4): 450 - 455. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Griselli, J. Herbert, W.L. Hutchinson, K.M. Taylor, M. Sohail, T. Krausz, and M.B. Pepys C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction J. Exp. Med., December 20, 1999; 190(12): 1733 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liuzzo, L. M. Biasucci, J. R. Gallimore, G. Caligiuri, A. Buffon, A. G. Rebuzzi, M. B. Pepys, and A. Maseri Enhanced inflammatory response in patients with preinfarction unstable angina J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1696 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Lagrand, C. A. Visser, W. T. Hermens, H. W. M. Niessen, F. W. A. Verheugt, G.-J. Wolbink, and C. E. Hack C-Reactive Protein as a Cardiovascular Risk Factor : More Than an Epiphenomenon? Circulation, July 6, 1999; 100(1): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir, C. J. Weir, W. Alwan, I. B. Squire, and K. R. Lees C-Reactive Protein and Outcome After Ischemic Stroke Stroke, May 1, 1999; 30(5): 981 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Manten, R. J. de Winter, M. C. Minnema, H. ten Cate, J. G. Lijmer, R. Adams, R. J.G. Peters, and S. J.H. van Deventer Procoagulant and proinflammatory activity in acute coronary syndromes Cardiovasc Res, November 1, 1998; 40(2): 389 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danesh, R. Collins, P. Appleby, and R. Peto Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease: Meta-analyses of Prospective Studies JAMA, May 13, 1998; 279(18): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gambino C-Reactive Protein—Undervalued, Underutilized Clin. Chem., November 1, 1997; 43(11): 2017 - 2018. [Full Text] [PDF]
|
|